These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 11464859

  • 21. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F.
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R, Ambros IM, Pötschger U, Amann G, Urban C, Fink FM, Schmitt K, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H, Ambros PF.
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [Abstract] [Full Text] [Related]

  • 24. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P.
    Cancer; 2002 Feb 01; 94(3):854-61. PubMed ID: 11857322
    [Abstract] [Full Text] [Related]

  • 25. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonini GP, De Bernardi B, Calabretta B.
    Cancer Res; 1999 Jul 15; 59(14):3365-8. PubMed ID: 10416595
    [Abstract] [Full Text] [Related]

  • 26. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas.
    Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT, Brodeur GM.
    Cancer Res; 1992 Apr 01; 52(7):1780-5. PubMed ID: 1551108
    [Abstract] [Full Text] [Related]

  • 27. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S, Ekstrom L, Lastowska M, Roberts P, Brodeur GM, Kees UR, Schwab M, Bown N.
    Genes Chromosomes Cancer; 2001 Jan 01; 30(1):87-90. PubMed ID: 11107180
    [Abstract] [Full Text] [Related]

  • 28. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.
    Clin Cancer Res; 1997 Oct 01; 3(10):1699-706. PubMed ID: 9815553
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
    Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):24-7. PubMed ID: 11464895
    [Abstract] [Full Text] [Related]

  • 33. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
    Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H.
    Cancer Res; 1995 Feb 15; 55(4):721-6. PubMed ID: 7850780
    [Abstract] [Full Text] [Related]

  • 34. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM.
    Genes Chromosomes Cancer; 2007 Oct 15; 46(10):936-49. PubMed ID: 17647283
    [Abstract] [Full Text] [Related]

  • 35. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Ohtsu K, Hiyama E, Ichikawa T, Matsuura Y, Yokoyama T.
    Clin Cancer Res; 1997 Jul 15; 3(7):1221-8. PubMed ID: 9815803
    [Abstract] [Full Text] [Related]

  • 36. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
    Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, Amann G, Kovar H, Horcher E, De Bernardi B, Michon J, Gadner H.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):1-4. PubMed ID: 11464855
    [Abstract] [Full Text] [Related]

  • 37. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O.
    J Clin Oncol; 2009 Mar 01; 27(7):1026-33. PubMed ID: 19171713
    [Abstract] [Full Text] [Related]

  • 38. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
    Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
    Clin Cancer Res; 2006 Jan 01; 12(1):131-8. PubMed ID: 16397034
    [Abstract] [Full Text] [Related]

  • 39. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D.
    Med Pediatr Oncol; 2001 Jan 01; 36(1):5-10. PubMed ID: 11464905
    [Abstract] [Full Text] [Related]

  • 40. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.
    Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schäfer KL, Terpe HJ, Lampert F, Boecker W, Dockhorn-Dworniczak B.
    Br J Cancer; 1998 Jun 01; 77(12):2223-9. PubMed ID: 9649137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.